Faron Pharmaceuticals Ltd.
Faron Announces Publication of Full Analysis from Phase 1/2 MATINS Trial of Bexmarilimab in Solid Tumors in Cell Reports Medicine
.
Faron Pharmaceuticals Limited (AIM:FARN, OTC:FPHAF), a specialist in macrophage reprogramming and anticancer immunotherapies, has shared its breakthrough.
Bexmarilimab monotherapy shows efficacy in achieving disease control and prolonged survival in late-stage metastatic solid tumorsCLEVER-1 targeting is safe and well-tolerated with no serious adverse effectsBexmarilimab induced macrophage activation and increased IFNɣ signaling in patients who achieved disease control and prolonged survival TURKU, Finland and BOSTON, Dec. 07, 2023 (GLOBE NEWSWIRE) Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical co
Presentation of Biomarker Analysis at ASCO streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.